Prostate cancer

Targeted TLR9-activation/STAT3-blocking abrogates immunosuppressive functions of myeloid-derived suppressor cells from late-stage prostate cancer patients
Dewan Md Sakib Hossain, Dayson Moreira, Qifang Zhang, Stephen J Forman, Sumanta Pal, Marcin Kortylewski

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P104; DOI: 10.1186/2051-1426-2-S3-P104
Cross-presentation of the oncofoetal tumor antigen 5T4 from irradiated prostate cancer cells - a key role for Hsp70
Josephine C Salimu, Lisa K Spary, Saly Al-Taei, Aled Clayton, Malcolm Mason, John Staffurth, Zsuzsanna Tabi

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P161; DOI: 10.1186/2051-1426-2-S3-P161
Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
Harpreet Singh, Ravi Madan, Jennifer Marte, Geraldine O'Sullivan-Coyne, Seth Steinberg, Christopher Heery, Jeffrey Schlom, James Gulley

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P155; DOI: 10.1186/2051-1426-2-S3-P155
Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
Sachin Puri, Jing Han, Bharat H Joshi, Daniel Healy, Janet Siebert, Christopher Paustian, Christopher Dubay, Keith S Bahjat, Brendan Curti, Walter J Urba, Bernard A Fox

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P257; DOI: 10.1186/2051-1426-2-S3-P257
Novel alphavirus-based vaccine induces strong immune responses against prostate-specific antigen (PSA) and mediates tumor cell elimination in a mouse model of prostate cancer
Vladimir Ryabov, Peter Pushko, Irina Tretyakova, Rikka Saito, Richard B Alexander, Elena N Klyushnenkova

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P221; DOI: 10.1186/2051-1426-1-S1-P221
Molecular analysis of antigen presentation machinery in circulating tumor cells from renal cell carcinoma and prostate cancer
Joshua M Lang, Jacob T Tokar, Jamie Sperger, Benjamin P Casavant, Scott M Berry, Lindsay N Strotman, David J Beebe

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P57; DOI: 10.1186/2051-1426-1-S1-P57
Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
Magdalena Kovacsovics-Bankowski, Lana Chisholm, Jonna Vercellini, Marka Crittenden, Scot Lary, Brendan Curti, Andrew Weinberg

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P255; DOI: 10.1186/2051-1426-1-S1-P255
Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
Benjamin Boyerinas, Jo A Tucker, Diane J Poole, Caroline Jochéms, Claudia Palena, Jeffrey Schlom, Kwong Y Tsang

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P202; DOI: 10.1186/2051-1426-1-S1-P202
Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
Stefanie N Linch, Melissa J Kasiewicz, William L Redmond

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P82; DOI: 10.1186/2051-1426-1-S1-P82
Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer
Seema Dubey, Sumedha Gunewardena, Peter Van Veldhuizen, J Brantley Thrasher, Dev Karan

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P55; DOI: 10.1186/2051-1426-1-S1-P55

Main menu

Prostate cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Prostate cancer

Pages